q12023-utilization-management-updates-1.1.23.pdf
Natiijooyinka Raadinta
Soo bandhiga 1151 - 1160 ee natiijooyinka 4296
Bixiye
QP101-22 Update for New to Market Medical Drugs: Lecanemab and Lifileucel
Taariikhda uu dhaqangalayo Barnaamijka: Des 16, 2022
Bixiye
QP108-22 MHCP Pharmacy Benefit Exclusion-Xolair
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP107-22 PCA Agency Requirements
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP104-22 Fee Schedule Requests Only Accepted from Contracted Providers
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP106-22 MHCP Pharmacy Benefit Exclusion Floxuridine
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP109-22 New Provider Toolkit
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP105-22 Provider Press Year-End 2022
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP103-22 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective February 1, 2023
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022
Bixiye
QP 102-22 MHCP Pharmacy Benefit Exclusion for Imjudo® and Tecvayli™
Taariikhda uu dhaqangalayo Barnaamijka: Des 14, 2022